Pharma Glycovax Inc
$8,477,787.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- August 31, 2020 – March 31, 2024
- Reference
- nrc-cnrc:172-2020-2021-Q2-957295
Published purpose
Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at the clinical level (phase I).
In plain English AI-generated
Funding supports Pharma Glycovax Inc in developing and clinically testing a Covid-19 vaccine candidate using O-glycan biomarkers, including toxicity confirmation and phase I trials.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.